

BLISS GVS PHARMA LIMITED
 Regd Office:102, Hyde Park, Sakivihar Road,
 Andheri (East), Mumbai - 400 072
STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS
FOR THE QUARTER AND HALF YEAR ENDED 30.09.2016

(Rs. In Lakhs)

SR. NO.	PARTICULARS	STANDALONE					
		QUARTER ENDED			HALF YEAR ENDED		YEAR ENDED
		30.09.2016 (UNAUDITED)	30.06.2016 (UNAUDITED)	30.09.2015 (UNAUDITED)	30.09.2016 (UNAUDITED)	30.09.2015 (UNAUDITED)	31.03.2016 (AUDITED)
1	INCOME FROM OPERATIONS						
	(a) SALES (NET OF EXCISE DUTY)	8895.58	6373.23	9268.54	15268.81	17251.37	31969.24
	(b) OTHER OPERATING INCOME	807.28	215.85	97.97	1023.13	140.02	669.11
	TOTAL INCOME FROM OPERATIONS(NET)	9702.86	6589.08	9366.51	16291.94	17391.39	32638.35
2	EXPENSES						
	a) COST OF MATERIALS CONSUMED	4613.94	2998.84	3715.49	7612.78	7294.29	13,647.00
	b) PURCHASE OF STOCK IN TRADE	-	-	-	-	36.37	36.37
	c) CHANGES IN INVENTORIES OF FINISHED GOODS	-	-	-	-	-	-
	WORK IN PROGRESS, STOCK IN TRADE	(538.99)	(160.88)	(191.83)	(699.87)	(175.93)	(132.09)
	d) EMPLOYEE BENEFITS EXPENSE	629.77	634.78	564.07	1264.55	1046.65	2188.89
	e) DEPRECIATION / AMORTISATION EXPENSES	144.72	144.30	157.67	289.02	292.88	585.24
	f) OTHER EXPENSES	1758.44	1390.35	2233.59	3148.79	3716.07	7288.36
	TOTAL EXPENSES	6607.88	5007.39	6478.99	11615.27	12210.33	23613.77
3	PROFIT FROM OPERATIONS BEFORE OTHER INCOME & FINANCE COSTS & EXCEPTIONAL ITEMS (1-2)	3094.98	1581.69	2887.52	4676.67	5181.06	9024.58
4	OTHER INCOME	179.20	741.85	836.24	921.05	1467.02	2307.57
5	PROFIT FROM ORDINARY ACTIVITIES BEFORE FINANCE COSTS (3+4)	3274.18	2323.54	3723.76	5597.72	6648.08	11332.15
6	FINANCE COSTS	244.36	290.08	416.24	534.44	707.42	1310.98
7	PROFIT FROM ORDINARY ACTIVITIES AFTER FINANCE COSTS BUT BEFORE EXCEPTIONAL ITEMS (5-6)	3029.82	2033.46	3307.52	5063.28	5940.66	10021.17
8	EXCEPTIONAL ITEMS	-	-	-	-	-	-
9	PROFIT FROM ORDINARY ACTIVITIES BEFORE TAX (7-8)	3029.82	2033.46	3307.52	5063.28	5940.66	10021.17
10	TAX EXPENSE (INCLUDING DEFERRED TAX)	1023.78	650.71	891.28	1674.49	1984.18	3459.70
11	NET PROFIT AFTER TAX FOR THE PERIOD (9 - 10)	2006.04	1382.75	2416.24	3388.79	3956.48	6561.47
12	MINORITY INTEREST	-	-	-	-	-	-
13	NET PROFIT AFTER TAX & MINORITY INTEREST (11-12)	2006.04	1382.75	2416.24	3388.79	3956.48	6561.47
14	PAID - UP EQUITY SHARE CAPITAL	1031.47	1031.47	1031.47	1031.47	1031.47	1031.47
15	RESERVES EXCLUDING REVALUATION RESERVE (AS PER BALANCE SHEET)	-	-	-	-	-	42175.96
16	BASIC AND DILUTED EPS (NOT ANNUALISED) OF FACE VALUE OF RE. 1/- EACH	1.94	1.34	2.34	3.29	3.84	6.36



STATEMENT OF ASSETS AND LIABILITIES AS AT 30TH SEPTEMBER, 2016

(Rs in Lakhs)

	Particulars	STANDALONE	
		Sep-16	Mar-16
I.	EQUITY AND LIABILITIES		
1	SHAREHOLDERS' FUNDS :		
	(a) Share Capital	1,031.47	1,031.47
	(b) Reserves and Surplus	45,620.43	42,175.96
	Sub-total - Shareholders' funds	46,651.90	43,207.43
2	Non- Current liabilities		
	(a) Long term Borrowings	617.53	1,184.07
	(b) Deferred tax liabilities (Net)	878.21	827.58
	(c) Long term provisions	181.04	186.84
	Sub-total - Non-current liabilities	1,676.78	2,178.49
3	Current liabilities		
	(a) Short term Borrowings	3,724.07	4,994.61
	(b) Trade payables	4,580.65	3,506.15
	(c) Other current liabilities	2,924.02	2,909.99
	(d) Short term provisions	851.22	1,671.81
	Sub-total -current liabilities	12,079.96	13,082.56
	Total.....	60,408.64	58,468.48
II.	ASSETS		
1	Non-current assets		
	(a) Fixed Assets	7,852.98	8,107.45
	(b) Non-current Investments	2,059.37	2,059.37
	(c) Long term loans and advances	11,188.85	11,044.68
	Sub-total - Non-current assets	21,101.20	21,211.50
2	Current assets		
	(a) Inventories	2,912.54	2,194.92
	(b) Trade receivables	21,252.78	25,057.83
	(c) Cash and Bank balances	9,435.44	5,689.76
	(d) Short term loans and advances	3,908.05	3,215.96
	(e) Other current assets	1,798.63	1,098.51
	Sub-total - Current assets	39,307.44	37,256.98
	Total.....	60,408.64	58,468.48

NOTES:-

1. THE ABOVE UNAUDITED FINANCIAL RESULTS WERE REVIEWED BY THE AUDIT COMMITTEE & WERE THERE AFTER APPROVED BY THE BOARD AT ITS MEETING HELD ON OCTOBER 26, 2016

2. THE COMPANY OPERATES PRIMARILY IN THE PHARMACEUTICAL BUSINESS AND HENCE HAS ONLY ONE REPORTABLE SEGMENT.

GEOGRAPHICAL SEGMENT DISCLOSURE:-

I) REVENUES WITHIN AND OUTSIDE INDIA FOR THE QUARTER ENDED SEPTEMBER 30, 2016 - RS. 583.79 LAKHS AND RS. 8311.79 LAKHS RESPECTIVELY

II) REVENUES WITHIN AND OUTSIDE INDIA FOR THE QUARTER ENDED JUNE 30, 2016 - RS. 498.89 LAKHS AND RS. 5874.34 LAKHS RESPECTIVELY

III) REVENUES WITHIN AND OUTSIDE INDIA FOR THE QUARTER ENDED SEPTEMBER 30, 2015- RS. 467.40 LAKHS AND RS. 8801.14 LAKHS RESPECTIVELY

IV) REVENUES WITHIN AND OUTSIDE INDIA FOR THE HALF YEAR ENDED SEPTEMBER 30, 2016- RS. 1082.68 LAKHS AND RS. 14186.12 LAKHS RESPECTIVELY

V) REVENUES WITHIN AND OUTSIDE INDIA FOR THE HALF YEAR ENDED SEPTEMBER 30, 2015- RS. 1141.83 LAKHS AND RS. 16109.54 LAKHS RESPECTIVELY

VI) REVENUES WITHIN AND OUTSIDE INDIA FOR THE YEAR ENDED MARCH 31, 2016- RS. 2045.73 LAKHS AND RS. 29923.51 LAKHS RESPECTIVELY

3. FIGURES FOR THE PREVIOUS PERIODS HAVE BEEN REGROUPED/REARRANGED WHEREVER NECESSARY.

PLACE : MUMBAI
DATE : 26TH OCTOBER 2016

FOR BLISS GVS PHARMA LTD

S. N. KAMATH
MANAGING DIRECTOR



BLISS GVS PHARMA LIMITED
 Regd Office. 102, Hyde Park, Sakivihar Road,
 Andheri (East), Mumbai - 400 072
 STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS
 FOR THE QUARTER AND HALF YEAR ENDED 30.09.2016

(Rs. In lakhs)

SR. NO.	PARTICULARS	CONSOLIDATED					
		QUARTER ENDED			HALF YEAR ENDED		YEAR ENDED
		30.09.2016 (UNAUDITED)	30.06.2016 (UNAUDITED)	30.09.2015 (UNAUDITED)	30.09.2016 (UNAUDITED)	30.09.2015 (UNAUDITED)	31.03.2016 (AUDITED)
1	INCOME FROM OPERATIONS						
	(a) SALES (NET OF EXCISE DUTY)	16033.69	13770.93	17599.38	29804.62	26947.11	53671.30
	(b) OTHER OPERATING INCOME	876.40	243.41	7.88	1119.81	148.31	1018.11
	TOTAL INCOME FROM OPERATIONS(NET)	16910.09	14014.34	17607.26	30924.43	27095.42	54689.41
2	EXPENSES						
	a) COST OF MATERIALS CONSUMED	7182.50	6586.63	8723.86	13769.13	11874.53	25,589.07
	b) PURCHASE OF STOCK I N TRADE	1004.49	90.96	129.75	1095.45	261.03	508.76
	c) CHANGES IN INVENTORIES OF FINISHED GOODS , WORK IN PROGRESS, STOCK IN TRADE	(914.46)	(105.41)	(303.41)	(1019.87)	(235.23)	(421.30)
	d) EMPLOYEE BENEFITS EXPENSE	1383.21	1081.01	997.41	2464.22	1752.14	3373.65
	e) DEPRECIATION / AMORTISATION EXPENSES	562.15	360.27	590.79	922.42	894.96	1326.00
	f) OTHER EXPENSES	3994.87	2424.50	3691.17	6419.37	5580.67	10108.90
	TOTAL EXPENSES	13212.76	10437.96	13829.57	23650.72	20128.10	40485.08
3	PROFIT FROM OPERATIONS BEFORE OTHER INCOME & FINANCE COSTS & EXCEPTIONAL ITEMS (1-2)	3697.33	3576.38	3777.69	7273.71	6967.32	14204.33
4	OTHER INCOME	224.99	871.64	761.46	1096.63	1408.87	2435.00
5	PROFIT FROM ORDINARY ACTIVITIES BEFORE FINANCE COSTS (3+4)	3922.32	4448.02	4539.15	8370.34	8376.19	16639.33
6	FINANCE COSTS	436.90	405.20	460.68	842.10	971.00	1819.86
7	PROFIT FROM ORDINARY ACTIVITIES AFTER FINANCE COSTS BUT BEFORE EXCEPTIONAL ITEMS (5-6)	3485.42	4042.82	4078.47	7528.24	7405.19	14819.47
8	EXCEPTIONAL ITEMS	-	-	-	-	-	-
9	PROFIT FROM ORDINARY ACTIVITIES BEFORE TAX (7 - 8)	3485.42	4042.82	4078.47	7528.24	7405.19	14819.47
10	TAX EXPENSE (INCLUDING DEFERRED TAX)	1528.51	1298.66	1277.53	2827.17	2607.44	4804.91
11	NET PROFIT AFTER TAX FOR THE PERIOD (9 - 10)	1956.91	2744.16	2800.94	4701.07	4797.75	10014.56
12	MINORITY INTEREST	591.89	678.67	496.70	1270.56	539.25	1766.30
13	NET PROFIT AFTER TAX & MINORITY INTEREST (11-12)	1365.02	2065.49	2304.24	3430.51	4258.50	8248.26
14	PAID - UP EQUITY SHARE CAPITAL	1031.47	1031.47	1031.47	1031.47	1031.47	1031.47
15	RESERVES EXCLUDING REVALUATION RESERVE (AS PER BALANCE SHEET)	-	-	-	-	-	40230.77
16	BASIC AND DILUTED EPS (NOT ANNUALISED) OF FACE VALUE OF RE. 1/- EACH	1.32	2.00	2.23	3.33	4.13	8.00



STATEMENT OF ASSETS AND LIABILITIES AS AT 30TH SEPTEMBER, 2016

(Rs. in Lakhs)

	Particulars	CONSOLIDATED	
		Sep-16	Mar-16
I.	EQUITY AND LIABILITIES		
1	SHAREHOLDERS' FUNDS :		
	(i) Share Capital	1,031.47	1,031.47
	(ii) Reserves and Surplus	44,184.34	40,230.77
	Sub-total - Shareholders' funds	45,215.81	41,262.24
2	Minority Interest	5,968.78	3,309.57
3	Non- Current liabilities		
	(i) Long term Borrowings	2,937.26	3,824.27
	(ii) Deferred tax liabilities (Net)	951.09	948.86
	(iii) Long term provisions	197.36	181.43
	Sub-total - Non-current liabilities	4,085.71	4,954.56
4	Current liabilities		
	(i) Short term Borrowings	4,685.01	6,212.38
	(ii) Trade payables	3,313.04	10,848.57
	(iii) Other current liabilities	13,411.93	5,275.63
	(iv) Short term provisions	2,472.34	4,315.23
	Sub-total -current liabilities	23,882.32	26,651.81
	Total.....	79,152.62	76,178.18
II.	ASSETS		
1	Non-current assets		
	(i) Fixed Assets	28,904.48	23,434.86
	(ii) Non-current Investments	273.90	11.02
	(iii) Long term loans and advances	6,556.15	5,677.48
	(iv) Other non current assets	0.25	-
	Sub-total - Non-current assets	35,734.78	29,123.36
2	Current assets		
	(i) Inventories	4,900.79	3,867.30
	(ii) Trade receivables	20,646.90	30,093.29
	(iii) Cash and Bank balances	11,167.39	7,817.66
	(iv) Short term loans and advances	5,104.17	5,041.92
	(v) Other current assets	1,598.59	234.65
	Sub-total - Current assets	43,417.84	47,054.82
	Total.....	79,152.62	76,178.18

NOTES:-

1. THE ABOVE UNAUDITED FINANCIAL RESULTS WERE REVIEWED BY THE AUDIT COMMITTEE & WERE THERE AFTER APPROVED BY THE BOARD AT ITS MEETING HELD ON OCTOBER 26, 2016

2. THE COMPANY OPERATES PRIMARILY IN THE PHARMACEUTICAL BUSINESS AND HENCE HAS ONLY ONE REPORTABLE SEGMENT.
GEOGRAPHICAL SEGMENT DISCLOSURE:-

- I) REVENUES WITHIN AND OUTSIDE INDIA FOR THE QUARTER ENDED SEPTEMBER 30, 2016 - RS. 2,131.97 LAKHS AND RS. 13,901.72 LAKHS RESPECTIVELY
 II) REVENUES WITHIN AND OUTSIDE INDIA FOR THE QUARTER ENDED JUNE 30, 2016- RS. 1,291.75 LAKHS AND RS. 12,479.18 LAKHS RESPECTIVELY
 III) REVENUES WITHIN AND OUTSIDE INDIA FOR THE QUARTER ENDED SEPTEMBER 30, 2015- RS. 2,053.47 LAKHS AND RS. 15,545.91 LAKHS RESPECTIVELY
 IV) REVENUES WITHIN AND OUTSIDE INDIA FOR THE HALF YEAR ENDED SEPTEMBER 30, 2016- RS. 3,423.72 LAKHS AND RS. 26,380.90 LAKHS RESPECTIVELY
 V) REVENUES WITHIN AND OUTSIDE INDIA FOR THE HALF YEAR ENDED SEPTEMBER 30, 2015- RS. 3,117.30 LAKHS AND RS. 23,829.81 LAKHS RESPECTIVELY
 VI) REVENUES WITHIN AND OUTSIDE INDIA FOR THE YEAR ENDED MARCH 31, 2016- RS. 5,413.38 LAKHS AND RS. 48,257.92 LAKHS RESPECTIVELY

3. FIGURES FOR THE PREVIOUS PERIODS HAVE BEEN REGROUPED/REARRANGED WHEREVER NECESSARY.

PLACE : MUMBAI
DATE : 26TH OCTOBER 2016

FOR BLISS GVS PHARMA LTD

S.N. KAMATH
MANAGING DIRECTOR

